Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. (Q39835436)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. |
scientific article |
Statements
1 reference
Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. (English)
1 reference
Martin Schrappe
1 reference
Thomas Klingebiel
1 reference
Martin Stanulla
1 reference
Felix Zintl
1 reference
Anja Möricke
1 reference
Alfred Reiter
1 reference
Martin Zimmermann
1 reference
Helmut Gadner
1 reference
Michael Dördelmann
1 reference
Lutz Löning
1 reference
Rita Beier
1 reference
Wolf-Dieter Ludwig
1 reference
Richard Ratei
1 reference
Jochen Harbott
1 reference
Joachim Boos
1 reference
Georg Mann
1 reference
Andreas Feldges
1 reference
Günter Henze
1 reference
Karl Welte
1 reference
Jörn-Dirk Beck
1 reference
Charlotte Niemeyer
1 reference
Udo Bode
1 reference
Christian Urban
1 reference
Helmut Wehinger
1 reference
Dietrich Niethammer
1 reference
Hansjörg Riehm
1 reference
German-Austrian-Swiss ALL-BFM Study Group
1 reference
19 February 2008
1 reference
Identifiers
1 reference